Summary

Middle East Cell Therapy Raw Materials Market Summary

The Middle East cell therapy raw materials market size was estimated at USD 39.2 million in 2024 and is expected to reach USD 169.8 million by 2033, expanding at a CAGR of 17.8% from 2025 to 2033. This growth is driven by increasing investments in regenerative medicine, the rising prevalence of chronic and rare diseases, and expanding research initiatives across countries such as the UAE, Saudi Arabia, and Qatar. Moreover, government-backed funding programs and collaborations between regional research institutes and international biotech firms are accelerating the adoption of advanced cell therapy products.

Rising Prevalence of Chronic & Rare Diseases

The growing burden of chronic and rare diseases in the Middle East is a key factor driving the demand for raw materials for cell therapy. Conditions such as cancer, diabetes, cardiovascular disorders, and genetic abnormalities are increasing in prevalence due to aging populations, urbanization, and changing lifestyle patterns. Many of these illnesses have limited treatment options with conventional medicine, pushing healthcare systems to adopt advanced therapeutic approaches such as regenerative medicine and cell-based interventions. As these therapies require consistent and high-quality inputs, there is a rising need for GMP-grade raw materials, including cell culture media, growth factors, cytokines, and cryopreservation agents, to ensure their efficacy, safety, and scalability of treatments.

Moreover, the shift towards personalized medicine in the region is amplifying this demand. As a result, healthcare providers increasingly focus on treatments tailored to individual patient profiles, necessitating specialized raw materials compatible with unique genetic and biological characteristics. The Middle East's growing network of research institutions, hospitals, and biotech firms is intensifying efforts in cell therapy development, creating a sustained requirement for reliable, regulatory-compliant raw materials. This trend is expected to gain momentum as governments invest in healthcare modernization and cross-border collaborations with global biotech companies expand access to cutting-edge therapeutic solutions.

Middle East Cell Therapy Raw Materials Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East cell therapy raw materials market based on product, end use, and country:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Media
• Sera
• Cell Culture Supplements
• Antibodies
• Reagents & Buffers
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Others
• Country Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East
o Saudi Arabia
o UAE
o Kuwait
o Qatar
o Oman
o Rest of Middle East

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Product
1.2.2. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Primary Research
1.6. Information or Data Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Market Model
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. List of Abbreviations
1.11. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising prevalence of chronic and rare diseases
3.2.1.2. Government-led healthcare investments
3.2.2. Market Restraint Analysis
3.2.2.1. High cost associated with the production and procurement of raw materials
3.2.2.2. Stringent regulations associated with cell therapies
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Product Business Analysis
4.1. Product Segment Dashboard
4.2. Middle East Cell Therapy Raw Materials Market: Product Movement Analysis
4.3. Middle East Cell Therapy Raw Materials Market Size & Trend Analysis, By Product, 2021 to 2033 (USD Million)
4.4. Media
4.4.1. Media Market, 2021 - 2033 (USD Million)
4.5. Sera
4.5.1. Sera Market, 2021 - 2033 (USD Million)
4.6. Cell Culture Supplements
4.6.1. Cell Culture Supplements Market, 2021 - 2033 (USD Million)
4.7. Antibodies
4.7.1. Antibodies Market, 2021 - 2033 (USD Million)
4.8. Reagents & Buffers
4.8.1. Reagents & Buffers Market, 2021 - 2033 (USD Million)
4.9. Others
4.9.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. End-use Business Analysis
5.1. End use Segment Dashboard
5.2. Middle East Cell Therapy Raw Materials Market: End-use Movement Analysis
5.3. Biopharmaceutical & Pharmaceutical Companies
5.3.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
5.4. CROs & CMOs
5.4.1. CROs & CMOs Market, 2021 - 2033 (USD Million)
5.5. Others
5.5.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Middle East Cell Therapy Raw Materials Market: Regional Estimates & Trend Analysis
6.1. Country Market Share Analysis, 2024 & 2033
6.2. Country Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
6.4. Middle East
6.4.1. Saudi Arabia
6.4.1.1. Key country dynamics
6.4.1.2. Competitive scenario
6.4.1.3. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. UAE
6.4.2.1. Key country dynamics
6.4.2.2. Competitive scenario
6.4.2.3. UAE market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Kuwait
6.4.3.1. Key country dynamics
6.4.3.2. Competitive scenario
6.4.3.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
6.4.4. Qatar
6.4.4.1. Key country dynamics
6.4.4.2. Competitive scenario
6.4.4.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
6.4.5. Oman
6.4.5.1. Key country dynamics
6.4.5.2. Competitive scenario
6.4.5.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
6.4.6. Rest of Middle East
6.4.6.1. Key country dynamics
6.4.6.2. Competitive scenario
6.4.6.3. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Position Analysis, 2024
7.4. Company Profiles
7.4.1. Thermo Fisher Scientific Inc.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Merck KGaA
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Actylis.
7.4.3.1. Overview
7.4.3.2. Product Benchmarking
7.4.3.3. Strategic Initiatives
7.4.4. ACROBiosystems
7.4.4.1. Overview
7.4.4.2. Product Benchmarking
7.4.4.3. Strategic Initiatives
7.4.5. STEMCELL Technologies
7.4.5.1. Overview
7.4.5.2. Product Benchmarking
7.4.5.3. Strategic Initiatives
7.4.6. Grifols, S.A.
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Charles River Laboratories
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. RoosterBio, Inc.
7.4.8.1. Overview
7.4.8.2. Product Benchmarking
7.4.8.3. Strategic Initiatives
7.4.9. PromoCell GmbH
7.4.9.1. Overview
7.4.9.2. Product Benchmarking
7.4.9.3. Strategic Initiatives
7.4.10. Danaher
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Sartorius Stedim Biotech
7.4.11.1. Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives